ESI-GROUP
20.10.2020 14:35:10 CEST | Business Wire | Press release
Launched in February 2020, the AMPLI project simulation, supported by the EIT Manufacturing and reuniting a consortium of five partners – ESI Group (Paris:ESI), coordinator of the project, Whirlpool, IPC (Innovation Plasturgie Composites), ENSAM and LMS (Laboratory for Manufacturing Systems & Automation) – will combine advantages of simulation and augmented reality to provide manufacturing workers with real-time knowledge and information. The project will bring an important step forward the digital transformation of European factories.
The plastics industry has already introduced enabling technologies to achieve zero-defect manufacturing and improve work cells flexibility such as in-mold sensors, in-line quality control, autonomous devices or predictive models. Augmented Reality (AR) offers new ways to interact not only with machines but also with manufacturing and product models. However, for further adoption, existing AR tools are still not specific enough to be relevant and need to offer dedicated platforms regarding each industrial domain.
The objective of the AMPLI project is to provide machine operators with real-time knowledge and information to improve decision-making and working procedures thanks to the development of an AR tool dedicated to the manufacturing value chain of polymer forming process. The AR tool will be based on the combination of plastic domain-based knowledge (from tuning, production and maintenance) and the integration of numerical simulation.
AMPLI project target 3 main benefits:
-
Improve manufacturing efficiency
- time reduction for tuning a work cell: -10%
- increase machinery availability by preventive maintenance: +8%
- reduction of training period of work force: -25%
- reduction of scraps: -10%
- Eliminate skill shortages by capturing and return process knowledge
- Increase attractivity of shop floor work by fostering the use of digital tools, which is appealing for young people. Work becomes more visual, accessibility increases and facilitates the training
AMPLI project approach is to embed and enable physically realistic virtual objects in a real environment to be interactive. It is based on the improvement of AR mechanisms and usability through:
- embedded process simulation results thanks to reduced order model
- customized plastic and composite processing interface by mixing measured information coming from the manufacturing work cell and information coming from models
The project is sponsored by the EIT Manufacturing (European Institute of Innovation & Technology) and is supported by a consortium of 5 European partners led by ESI Group. Together, and for a period of one year, the consortium partners will be working on developing, testing and validating AR and simulation technology dedicated to a thermoforming process.
ESI will be the integrator of the final output based on existing AR tool. This step will be particularly challenging and key as AR need real-time information to be efficient which will not be possible without ESI’s expertise and innovation technologies like its model-order reduction platform. IPC will provide knowledge rules regarding setting and supervision. They will use their skills in machine interoperability and process control as guidance for the project. Moreover, IPC simulates currently thermoforming process using ESI software PAM-FORM.
LMS has extensive experience in developing AR application for the manufacturing domain to support different steps of the lifecycle. Among other AR apps, LMS has developed an AR solution to support the maintenance phase of injection molds.
ENSAM will develop AR features to mix manufacturing process simulation with reality.
Whirlpool as plastic converter will provide requirements and a pilot case dedicated to thermoforming to test and validate the product at an industrial scale.
AMPLI will bring to the market a new product with AR integrating both plastic domain knowledge and simulation as differentiator.
In mid-term, such benefits will be transferred to other manufacturing processes.
Project title
: Augmented Mold for setting and supervision of PLastIc product manufacturing
Project Duration:
12 months
Project Consortium:
ENSAM, ESI Group, IPC, LMS, Whirlpool
About ESI
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.
Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI
LinkedIn / Facebook / Twitter / Youtube
About the EIT & EIT Manufacturing
The European Institute of Technology and Innovation (EIT) is a body of the European Union and is an integral part of the Horizon 2020 program. EIT was established to support the innovators to change their best ideas to products, services and job positions for Europe. EIT consists of 8 Knowledge and Innovation Communities: EIT Manufacturing, EIT Climate-KIC, EIT Digital, EIT Food, EIT Health, EIT InnoEnergy, EIT RawMaterials, and EIT Urban Mobility.
EIT Manufacturing’s main goal is to bring European stakeholders focused on manufacturing together in innovation ecosystems that add unique value to European products, processes and services and inspire the creation of globally competitive and sustainable manufacturing. EIT Manufacturing associates more 50 organizations (universities, research institutes and business), such as Volkswagen, Volvo, Darmstadt University of Technology, the French Alternative Energies and Atomic Energy Commission (CEA), Siemens, Slovak University of Technology in Bratislava, Phillips, Procter & Gamble, and Whirlpool Europe to name a few.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005720/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
